These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 11048813)

  • 1. Prodromal schizophrenia and atypical antipsychotic treatment.
    Kablinger AS; Freeman AM
    J Nerv Ment Dis; 2000 Oct; 188(10):642-52. PubMed ID: 11048813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cognitive deficits in first episode psychosis patients and people at risk for psychosis: from diagnosis to treatment].
    Lecardeur L; Meunier-Cussac S; Dollfus S
    Encephale; 2013 May; 39 Suppl 1():S64-71. PubMed ID: 23528322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of atypical antipsychotics on quality of life in patients with schizophrenia.
    Awad AG; Voruganti LN
    CNS Drugs; 2004; 18(13):877-93. PubMed ID: 15521791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifying vulnerability markers in prodromal patients: a step in the right direction for schizophrenia prevention.
    Knowles L; Sharma T
    CNS Spectr; 2004 Aug; 9(8):595-602. PubMed ID: 15273652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Untreated initial psychosis: its relation to quality of life and symptom remission in first-episode schizophrenia.
    Ho BC; Andreasen NC; Flaum M; Nopoulos P; Miller D
    Am J Psychiatry; 2000 May; 157(5):808-15. PubMed ID: 10784476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early signs, diagnosis and therapeutics of the prodromal phase of schizophrenia and related psychotic disorders.
    Larson MK; Walker EF; Compton MT
    Expert Rev Neurother; 2010 Aug; 10(8):1347-59. PubMed ID: 20662758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early neuroleptic intervention in schizophrenia: are prodromal symptoms valid predictors of relapse?
    Gaebel W; Frick U; Köpcke W; Linden M; Müller P; Müller-Spahn F; Pietzcker A; Tegeler J
    Br J Psychiatry Suppl; 1993 Sep; (21):8-12. PubMed ID: 8105814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The schizophrenia prodrome revisited: a neurodevelopmental perspective.
    Cornblatt BA; Lencz T; Smith CW; Correll CU; Auther AM; Nakayama E
    Schizophr Bull; 2003; 29(4):633-51. PubMed ID: 14989404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prodromal states in schizophrenia.
    Gaebel W; Jänner M; Frommann N; Pietzcker A; Köpcke W; Linden M; Müller P; Müller-Spahn F; Tegeler J
    Compr Psychiatry; 2000; 41(2 Suppl 1):76-85. PubMed ID: 10746908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Revisiting the relapse predictive validity of prodromal symptoms in schizophrenia.
    Gaebel W; Riesbeck M
    Schizophr Res; 2007 Sep; 95(1-3):19-29. PubMed ID: 17630253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Incidence of the deficit form in refractory schizophrenia].
    Samuelian JC
    Encephale; 1996 Jun; 22 Spec No 2():19-23. PubMed ID: 8767037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relation of familial schizophrenia to negative symptoms but not to the deficit syndrome.
    Malaspina D; Goetz RR; Yale S; Berman A; Friedman JH; Tremeau F; Printz D; Amador X; Johnson J; Brown A; Gorman JM
    Am J Psychiatry; 2000 Jun; 157(6):994-1003. PubMed ID: 10831482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome in schizophrenia: beyond symptom reduction.
    Meltzer HY
    J Clin Psychiatry; 1999; 60 Suppl 3():3-7; discussion 8. PubMed ID: 10073370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prodromal symptoms and prevention of relapse in schizophrenia.
    Herz M
    J Clin Psychiatry; 1985 Nov; 46(11 Pt 2):22-5. PubMed ID: 2865253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A program for relapse prevention in schizophrenia: a controlled study.
    Herz MI; Lamberti JS; Mintz J; Scott R; O'Dell SP; McCartan L; Nix G
    Arch Gen Psychiatry; 2000 Mar; 57(3):277-83. PubMed ID: 10711914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Is there a primary prevention of schizophrenic psychiasis?].
    Klosterkötter J; Schultze-Lutter F
    Fortschr Neurol Psychiatr; 2001 Sep; 69 Suppl 2():S104-12. PubMed ID: 11533860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective study of prodromal symptoms in schizophrenic relapse.
    Heinrichs DW; Carpenter WT
    Am J Psychiatry; 1985 Mar; 142(3):371-3. PubMed ID: 2857535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Negative priming (cognitive inhibition) in psychiatric patients: effect of neuroleptics.
    David AS
    J Nerv Ment Dis; 1995 May; 183(5):337-9. PubMed ID: 7745390
    [No Abstract]   [Full Text] [Related]  

  • 19. Survey on schizophrenia treatment in Mexico: perception and antipsychotic prescription patterns.
    Apiquian R; Fresán A; de la Fuente-Sandoval C; Ulloa RE; Nicolini H
    BMC Psychiatry; 2004 Apr; 4():12. PubMed ID: 15109398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of atypical versus typical antipsychotic medication on earnings of schizophrenia patients : estimates from a prospective naturalistic study.
    Salkever D; Slade E; Karakus M
    Pharmacoeconomics; 2006; 24(2):123-39. PubMed ID: 16460134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.